Dr. Nissen Recaps PCSK9 News from ACC (Video)

If you couldn’t make it to the recent American College of Cardiology meeting to hear the big PCSK9 inhibitor trial presentations in person, we’ve got the next best thing: An expert’s take on the major PCSK9 study reports from the meeting.

In this three-minute video, Cleveland Clinic Cardiovascular Medicine Chair Steven Nissen, MD, sums up results and implications of four trials of importance presented at the meeting:

• The long-awaited FOURIER outcomes study of evolocumab
• The EBBINGHAUS substudy of FOURIER assessing for neurocognitive safety
• The SPIRE studies shedding light on why development of bococizumab has been discontinued
• The phase 2 ORION-1 trial of the next-generation PCSK9 inhibitor known as inclisiran